Finite Mixture Models, a Flexible Alternative to Standard Modeling Techniques for Extrapolated Mean Survival Times Needed for Cost-Effectiveness Analyses.

OBJECTIVES To compare finite mixture models with common survival models with respect to how well they fit heterogenous data used to estimate mean survival times required for cost-effectiveness analysis. METHODS Publicly available overall survival (OS) and progression-free survival (PFS) curves were digitized to produce nonproprietary data. Regression models based on the following distributions were fit to the data: Weibull, lognormal, log-logistic, generalized F, generalized gamma, Gompertz, mixture of 2 Weibulls, and mixture of 3 Weibulls. A second set of analyses was performed based on data in which patients who had not experienced an event by 30 months were censored. Model performance was compared based on the Akaike information criterion (AIC). RESULTS For PFS, the 3-Weibull mixture (AIC = 479.94) and 2-Weibull mixture (AIC = 488.24) models outperformed other models by more than 40 points and produced the most accurate estimates of mean survival times. For OS, the AIC values for all models were similar (all within 4 points). The means for the mixture 3-Weibulls mixture model (17.60 months) and the 2-Weibull mixture model (17.59 months) were the closest to the Kaplan-Meier mean estimate of (17.58 months). The results and conclusions from the censored analysis of PFS were similar to the uncensored PFS analysis. On the basis of extrapolated mean OS, all models produced estimates within 10% of the Kaplan-Meier mean survival time. CONCLUSIONS Finite mixture models offer a flexible modeling approach that has benefits over standard parametric models when analyzing heterogenous data for estimating survival times needed for cost-effectiveness analysis.

[1]  Richard Grieve,et al.  Extrapolation of Survival Data in Cost-effectiveness Analyses , 2013, Medical decision making : an international journal of the Society for Medical Decision Making.

[2]  J. Karnon,et al.  Extrapolation of Survival Curves Using Standard Parametric Models and Flexible Parametric Spline Models: Comparisons in Large Registry Cohorts with Advanced Cancer , 2020, Medical decision making : an international journal of the Society for Medical Decision Making.

[3]  D. Schadendorf,et al.  Improved survival with ipilimumab in patients with metastatic melanoma. , 2010, The New England journal of medicine.

[4]  J. Crowley,et al.  End points and statistical considerations in immuno-oncology trials: impact on multiple myeloma , 2017, Future oncology.

[5]  G. Dranitsaris,et al.  Modelling the Survival Outcomes of Immuno-Oncology Drugs in Economic Evaluations: A Systematic Approach to Data Analysis and Extrapolation , 2017, PharmacoEconomics.

[6]  J. Kalbfleisch,et al.  The Statistical Analysis of Failure Time Data , 1980 .

[7]  A. Briggs,et al.  Estimating Lifetime Benefits Associated with Immuno-Oncology Therapies: Challenges and Approaches for Overall Survival Extrapolations , 2019, PharmacoEconomics.

[8]  Haitao Chu,et al.  Parametric survival analysis and taxonomy of hazard functions for the generalized gamma distribution , 2007, Statistics in medicine.

[9]  Praveen Thokala,et al.  A Review of Survival Analysis Methods Used in NICE Technology Appraisals of Cancer Treatments: Consistency, Limitations, and Areas for Improvement , 2019, Medical decision making : an international journal of the Society for Medical Decision Making.

[10]  Geoffrey J. McLachlan,et al.  Finite Mixture Models , 2019, Annual Review of Statistics and Its Application.

[11]  Robert Tibshirani,et al.  The Elements of Statistical Learning: Data Mining, Inference, and Prediction, 2nd Edition , 2001, Springer Series in Statistics.

[12]  M. Schlichting,et al.  Evaluation of survival extrapolation in immuno-oncology using multiple pre-planned data cuts: learnings to aid in model selection , 2020, BMC Medical Research Methodology.